The IFN-Ɣ +874 A/T polymorphism is associated with malignant breast cancer in a population from the southwest of Iran

Hadi Rezaeean1, Gholam Abbas Kaydani2, Najmaldin Saki2, Sasan Razmjoo3, Maryam Labibzadeh4 and Hamid Yaghooti5*

Abstract

Objective: Breast cancer (BC) is one of the most common diseases in women globally, with an increasing number of deaths associated with it. Recently the role of polymorphisms in the genes encoding cytokines and immune cells has been demonstrated. This study aimed to evaluate the association of IFN-Ɣ +874 A/T polymorphism with BC clinical symptoms.

Results: The study included 88 women with BC and 88 healthy women who had no history of cancer and were matched for age and sex. Allele-specific oligonucleotide-polymerase chain reaction technique was used to investigate the IFN-Ɣ polymorphism. Clinical data were obtained from the patients' records. Our results showed that the frequencies of genotypes in the BC patients were not significantly different from the control subjects. However, in the patients, the AT genotype was associated with the risk of malignant BC. The age at BC diagnosis was not different in patients with AA and AT genotypes; however, it was significantly earlier in HER2 negative subjects (p = 0.002). Given the higher frequency of AT in malignant BC patients, our results confirm the association of the IFN-Ɣ polymorphism with the disease's progression to a malignant state.

Keywords: Interferon-Ɣ, Polymorphism, Breast cancer, Malignant

Introduction

Breast cancer (BC) is the most common cancer in women accounting for nearly 14% of all cancer-related deaths [1]. The immune system is one of the factors that have a dual role in cancer. On the one hand, this system prevents angiogenesis and proliferation of cancer cells, and on the other hand, it promotes the formation and metastasis of cancer cells to different parts of the body [2, 3]. Interferons (IFNs) are a family of cytokines involved in regulating immune system responses against viral infection and cancer cells [4]. It is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response and by CD4 Th1 and CD8 cytotoxic T lymphocytes [5].

The IFN-Ɣ coding gene is located on chromosome 12 in the 12q24 region, consisting of 4 exons and three introns [6]. Recently a single nucleotide polymorphism (SNP) has been identified at position +874 (IFN-Ɣ +874 A/T, rs2430561) at intron 1 of the IFN-Ɣ coding gene. The +874 region is the binding site of the nuclear factor kappa light chain enhancer of activated B cells (NF-kB) involved in the production of IFN-Ɣ. The A to T transversion in the +874 region causes AA, AT, and TT genotypes to decrease, average, and increase IFN-Ɣ production, respectively [7]. Given that IFN-Ɣ is involved in the expression of immune system responses against cancer cells, recent studies have shown that the rs2430561
polymorphism is involved in the BC’s pathogenesis. It has been reported that the frequency of the IFN-Ɣ T/T genotype was higher in BC patients than in the control group, and the T/T genotype increased the risk of BC [8]. However, other studies showed no relationship between IFN-Ɣ +874 A/T polymorphism and the BC’s risk [9]. The relationship between IFN-Ɣ polymorphism and BC patients’ pathophysiological symptoms has not been evaluated so far in our population. Suppose the association of this genetic factor with the incidence and clinical condition of BC be demonstrated in a population. In that case, it can be used as a prognostic marker to evaluate the disease. Therefore, in this study, we investigated the prevalence of IFN-Ɣ +874 A/T polymorphism in cancer and healthy individuals and its association with the patients’ pathologic markers and clinical status.

Main text
Materials and methods
Study population
Eighty-eight women with BC and Eighty-eight healthy women who had no family history of cancer and other malignancies were included in the study. Patients were either new cases or treated, referred to the Golestan Hospital in Ahvaz, southwest of Iran, between 2014 and 2017. The mean age of the patients was 47.2 ± 9.2. The controls also had the same age and sex as the patients. Before selecting control subjects, they were asked about their previous history and that of their family, and individuals with no family history of cancer and no present disease were selected. These people were selected from the clients who were referred to the laboratory for a checkup. The selection of BC patients was based on their records and an oncologist’s diagnosis, with no concomitant disease. This study was approved by the ethics committee of Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1396.717), and informed consent was obtained from each subject participating in the study.

DNA extraction
Approximately 2 mL of peripheral blood was collected from all subjects in acetic acid-containing anticoagulant tubes. DNA was extracted from blood samples using Yektatajiz Azma kit (Iran) according to the manufacturer’s protocol. The extracted DNAs were stored at −20 °C until analysis.

DNA analysis
IFN-Ɣ +874A/T polymorphism was analyzed by allele-specific oligonucleotide polymerase chain reaction (ASO-PCR). The sequence of primers used is shown in Table 1 [8]. Two separate microtubes were used for each sample, all of which were identical for each PCR reaction with reverse primer, but the forward primers were different and specific to the A and T alleles in each tube. The reaction solution volume was 25 μL containing 10 μL distilled water (DW), 10 μmol PCR 2 × Master mix, 200 ng DNA, 20 pmol forward, and 20 pmol reverse primers. Conditions for performing PCR cycles for 35 cycles were as follow 95 °C for 5 min, 95 °C for 45 s, 55 °C for 45 s, 72 °C for 1 min with final extension for 3 min at 72 °C.

The PCR products were then characterized by 2% agarose gel electrophoresis. The bands associated with the AA and AT genotypes were both 262 bp in length.

Statistical analysis
To describe the data, we used frequencies and percentages. A Chi-square test was used to compare the allele and genotype frequencies. Odds Ratio (OR) was calculated using the Mantel–Haenszel test to evaluate the association between AA and AT genotypes and BC and its clinical parameters. The Mann–Whitney U test was applied for comparison of the quantitative variables. All analyses were performed using SPSS version 22. P < 0.05 was considered to be statistically significant.

Results
Prevalence of the IFN-Ɣ +874 A/T genotypes in the patients and control subjects
Frequencies of IFN-Ɣ +874 A/T genotypes and alleles in our population are shown in Table 2. It was found that the prevalent genotype was AT in both groups, whereas no subject with TT genotype was detected. We also found no statistically significant difference between the frequency of genotypes in the control group and patients. The OR for AA genotype versus AT genotype was 0.92 (95% CI 0.4–2.1, p-value = 0.8) for BC.

Association between IFN-Ɣ +874 A/T variants and clinical parameters
We extracted data from patients’ records to evaluate the relationship between patients’ polymorphism and clinical symptoms. We examined the association of each of the recorded clinical parameters with the polymorphism genotypes. The results showed that AT genotype frequency in both benign and malignant cancer patients was higher than that of AA genotype. However, the

Table 1  Primers used for the detection of IFN-Ɣ +874 A/T polymorphism

| Primer | Sequence | Product length |
|--------|----------|----------------|
| Forward | 5′-ttcttacacaaacaaatcaatc-a-3′ | 262 bp |
| Reverse | 5′-tcaacaaagtgtatcaatc-3′ | |


percentage of patients with the AT genotype was higher in malignant patients than the benign patients. The OR for AT genotype versus the AA genotype to have a malignant phenotype was 5.3 (95% CI 1.1–26, p-value = 0.05).

For other recorded parameters of the disease, including the occurrence of metastasis, right versus left affected breast, and HER2, ER, and PR status, the frequency of the AT genotype was higher than that of AA genotype. However, the IFN-Ɣ+874 A/T AT genotype was not significantly associated with any of these clinical parameters (Table 3). The alleles of the polymorphism also did not show significant associations with the parameters. Similarly, the genotypes’ frequency was not different in patients with stages I to IV of BC based on a Chi-square analysis (Additional file 1: Table S1).

Also, we analyzed two other clinical parameters concerning the genotypes. The patients’ ages at the first diagnosis of BC and tumor size were recorded in the patients and were compared in the AA and AT genotypes. The age of diagnosis was 46.8 and 47.3 years in patients with AA and AT genotype, respectively (p = 0.6), and tumor size was 2.6 vs. 2.7 for these genotypes, respectively (p = 0.97). The differences were not statistically significant. However, it was notable that the age of diagnosis was significantly different concerning HER2. It was found that HER2 negative patients represent earlier BC diagnosis age than HER2 positive patients (42.4 vs. 48.9, p = 0.002).

### Discussion

BC is one of the most common neoplasms worldwide, with an increased incidence of women’s deaths over the past few years [10, 11]. Various therapies have been used to control the spread of BC so far. However, no effective treatment can completely eradicate BC cells in the body and prevent recurrence after initial treatment [12].

There is also a significant relationship between mutations in genes encoding cytokines and BC [13]. Research to date has identified many mutations in the genes encoding inflammatory cytokines. However, among these mutations, the IFN-γ gene expression (rs2430561) appears to play an essential role in the pathogenesis of BC and its response to treatment [14]. For this purpose, the study of Kamali-Sarvestani et al. conducted on women with BC and healthy women showed that TT genotype frequency was higher in female patients than in healthy women. However, no significant association was found between IFN-Ɣ+874 A/T polymorphism and the incidence of BC in women [8]. Also, the study by Gonullu et al. was performed to evaluate the association of IFN-Ɣ, IL-6, IL-10, tumor growth factor-β (TGF-β) and Tumor

### Table 2

|                  | AA (%) | AT (%) | TT (%) | A (%) | T (%) | p-value |
|------------------|--------|--------|--------|-------|-------|---------|
| Breast cancer    | 13 (14.8%) | 75 (85.2%) | 0 (0%) | 101 (57.4%) | 75 (42.6%) | 0.8     |
| Controls         | 14 (15.9%) | 74 (84.1%) | 0 (0%) | 102 (58%)  | 74 (42%)  | 0.9     |

### Table 3

|                  | AA 1.0-ref | AT | OR for AT vs AA (95% CI) | p-value | A 1.0-ref | T | OR for T vs A (95% CI) | p-value |
|------------------|------------|----|--------------------------|---------|-----------|---|----------------------|---------|
| Malignancy       | 3 (6.5)    | 44 (93.5) | 5.3 (1.1–26)            | 0.05    | 50 (53.2) | 44 (46.8) | 1.5 (0.7–3) | 0.3     |
| Benign           | 11 (27)    | 30 (73)   |                          |         | 52 (62.5) | 30 (37.5) |           |         |
| Metastasis       | 10 (13.5)  | 64 (86.5) | 1.7 (0.4–7.4)           | 0.4     | 84 (56.8) | 64 (43.2) | 1.2 (0.5–2.7) | 0.7     |
| No metastasis    | 3 (21.4)   | 11 (78.6) |                          | 0.6     | 48 (58.5) | 34 (41.5) | 1.1 (0.6–2) | 0.8     |
| Right            | 7 (17.1)   | 34 (82.9) | 0.7 (0.2–2.7)           |         | 48 (58.5) | 34 (41.5) | 1.1 (0.6–2) | 0.8     |
| Left             | 6 (13)     | 40 (87)   |                          |         | 52 (56.5) | 40 (43.5) |           |         |
| HER 2 positive   | 6 (11.3)   | 47 (88.7) | 2.3 (0.6–8.5)           | 0.2     | 59 (55.7) | 47 (44.3) | 0.8 (0.4–1.6) | 0.5     |
| HER 2 negative   | 5 (22.7)   | 17 (77.3) |                          |         | 27 (61.4) | 17 (38.6) |           |         |
| PR positive      | 8 (14.3)   | 48 (85.7) | 1.1 (0.3–4.8)           | 0.87    | 64 (57.1) | 48 (42.9) | 0.97 (0.5–2) | 0.9     |
| PR negative      | 3 (15.8)   | 16 (84.2) |                          |         | 22 (57.9) | 16 (42.1) |           |         |
| ER positive      | 8 (13.3)   | 52 (86.7) | 1.6 (0.4–7)            | 0.5     | 68 (56.7) | 52 (43.3) | 0.87 (0.4–1.97) | 0.7     |
| ER negative      | 3 (20)     | 12 (80)  |                          |         | 18 (60)   | 12 (40)   |           |         |

Data are expressed as number (%)
necrosis factor-α (TNF-α) polymorphisms with the disease. Mutations in the IL-6 and IL-10 coding genes were found to play a role in BC progression, whereas mutations in the IFN-1, TGF-β, and TNF-α coding genes did not play a role in BC pathogenesis [9]. On the other hand, Karakus et al. showed that AT and AA genotypes resulted from IFN-γ +874 A/T polymorphism and TNF-b p252 GG from TNF-b p252 (A>G) in women with BC were higher than in normal women. It was found that these genotypes promote the progression of BC cells [15].

Our results showed that the frequency of AT genotype was higher in BC and control group compared to AA genotype. However, the genotypes were not associated with the disease (p=0.8). No TT genotype was observed in the patients, and no significant relationship between the AA/AT genotypes and the disease incidence.

Parihar et al’s study showed that HER2-positive BC cells stimulate the immune system and increase this cytokine production due to polymorphisms in the interferon-gamma gene concomitant with the production of interferon-gamma in BC HER2-positive patients with reduced disease progression [16].

In a study by Esther et al., the results of their studies showed that there was no relationship between gamma interferon polymorphism and stage, disease, and lymph node involvement [17]. A study by Hao et al. showed that IFN-γ gene polymorphism is associated with increased metastasis of cancer cells and increased proliferation. Also, it was shown that the incidence of polymorphism in stages III and IV was higher than in stages I and II, indicating an impairment of IFN-γ secretion due to polymorphism and disease progression [18].

In the present study, the data analysis results showed a significant relationship between the polymorphism genotype and the malignant phenotype. This finding is in accordance with the earlier studies that the IFN-γ +874 A/T polymorphism is associated with the disease’s progression to a malignant phenotype. However, the polymorphism was not correlated with the disease stages after classification of the patients to four clinical stages. An essential parameter regarding BC is the age of presentation and diagnosis of the disease. The diagnosis age was not different in the AA and AT genotypes of IFN-γ +874 A/T polymorphism. However, it was found that the HER2 status of patients is a significant factor in this regard. The frequency of single nucleotide polymorphisms and their clinical correlations are different among populations. A consensus conclusion regarding their significance cannot be achieved due to the limited number of BC subjects and the cross-sectional nature of the studies. Hence, the individual studies are necessary to conduct in different populations to be analyzed through a meta-analysis study.

Conclusion
Although there was no statistically significant relationship between the frequency of genotypes and BC, our results showed that patients with the IFN-γ +874 A/T AT genotype were at higher risk of progression to a malignant state. Therefore, having an AA genotype would be in favor of a better prognosis of the disease.

Limitation
Patients were not followed up for response to treatment. The prognostic role of IFN-γ+874 A/T polymorphism of patients was not evaluated. The cytokine production related to IFN-γ +874 A/T polymorphism was not evaluated.

Abbreviations
BC: Breast cancer; INF: Interferon; SNP: Single nucleotide polymorphism.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13104-021-05543-6.

Additional file 1: Table S1. Frequency of the AA and AT genotypes in different stages of BC.

Acknowledgements
We wish to thank all our colleagues in Golestan Hospital and the Ahvaz Jundishapur University of Medical Sciences for their work’s financial support.

Authors’ contributions
HY has conceived the manuscript and revised it. HR and GAK wrote the manuscript. NS and SS provided clinical data and information. ML performed the technical tests. All authors read and approved the final manuscript.

Funding
This work was financially supported by a Grant (TH96/10) from the vice chancellor for the Ahvaz Jundishapur University of Medical Sciences’s research affairs.

Availability of data and materials
The datasets used analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All the procedures performed in the study involving human participants were following the ethical standards of the local ethics committee of Ahvaz Jundishapur University of Medical Sciences (IRAJUMS.REC.1396.717), as well as the 1964 Helsinki declaration. Written informed consent was obtained from all patients and normal subjects.

Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1 High Institute for Education and Research in Transfusion Medicine, Tehran, Iran. 2 Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3 Department of Clinical Oncology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4 Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 5 Hyperlipidemia Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Received: 27 October 2020   Accepted: 24 March 2021

Published online: 20 April 2021

References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
2. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–81.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–64.
4. Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847.
5. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-y, an overview of signals, mechanisms, and functions. J Leukoc Biol. 2004;75(2):163–89.
6. Calvo J, Martínez N, Etxagibel A, Calleja S, Sáez-Torres C, Sedeño M, et al. Allelic frequencies of polymorphic variants of cytokine genes (IL1A, IL1B, IL1RN, IL6, IL10, IL12p40, and IFNG) in a Spanish population. Immunologia. 2002;21(2):76–86.
7. Pravica V, Peney C, Stevens A, Lee J-H, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-y gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-y production. Hum Immunol. 2000;61 (9):863–6.
8. Kamali-Sarvestani E, Merat A, Talei A-R. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-α and TNF-β) and gamma interferon (IFN-γ) among Iranian women with breast cancer. Cancer Lett. 2005;223(1):113–9.
9. Gonullu G, Basturk B, Evrensel T, Oral B, Gozkarnan A, Alanavoglugi O. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J. 2007;28(11):1728–33.
10. Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, et al. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Breast Cancer Res Treat. 2010;123(3):733–45.
11. Nguyen DX, Masaquè J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007;8(5):341.
12. De Langhe S, Pelucchi T, Veldman L, Remouchamps V, van Greveling A, Gilsoul M, et al. Factors modifying the risk for developing acute skin toxicity after whole-breast intensity-modulated radiotherapy. BMC Cancer. 2014;14(1):711.
13. Eras N, Daloglu FT, Çolak T, Guler M, Akbas E. The correlation between IL-1β-C31T gene polymorphism and susceptibility to breast cancer. J Breast Cancer. 2019;22(2):210–8.
14. Li C-J, Dai Y, Fu Y-J, Tian J-M, Li J-L, Lu H-J, et al. RETRACTED ARTICLE: correlations of IFN-γ genetic polymorphisms with susceptibility to breast cancer: a meta-analysis. Tumor Biol. 2014;35(7):6867–77.
15. Karakus N, Kara N, Ulusoys AO, Ozaslan C, Berk Y. Tumor necrosis factor-alpha and beta and interferon-gamma gene polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 2011;30(6):371–7.
16. Parhar R, Nadelia P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, et al. A phase I study of interferekin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients. Clin Cancer Res. 2004;10(15):5027–37.
17. Erdei E, Kang H, Meisner A, White K, Pickett G, Baca C, et al. Polymorphisms in cytokine genes and serum cytokine levels among New Mexican women with and without breast cancer. Cytokine. 2010;51(1):18–24.
18. Hao K, Yan Z, Shuang Y, Sun J, Tao S, Fu W, et al. Association between interferon-gamma 13-CA-repeats polymorphism and metastasis of nasopharyngeal carcinoma in a population of northern China. Int J Clin Exp Pathol. 2015;8(6):7409.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.